Patient Case: A 67-Year-Old Man With Relapsed/Refractory DLBCL

CT071, a chimeric antigen receptor T-cell therapy candidate, had an investigational new drug application cleared by the FDA for patients with relapsed/refractory multiple myeloma and primary plasma cell leukemia.

A real-world analysis found that patients with acute coronary syndrome who were also diagnosed with a hematologic malignancy had worse survival outcomes, and patients with multiple myeloma were overrepresented in the population.

During a Targeted Oncology™ Case-Based Roundtable™ event, Uma Borate, MBBS, moderated discussion of physicians' familiarity with diagnosis and treatment of blastic plasmacytoid dendritic cell neoplasm. This is the second of 2 articles based on this event.

As a monotherapy, bispecific antibodies have demonstrated antitumor activity in heavily pretreated patients with B-cell and T-cell hematologic malignancies, but much work is needed to determine the optimal setting.

With a partial clinical hold in place, patient enrollment must halt in the phase 1 NX-2127-001 trial.

In the third article of this series, Amer Zeidan, MBBS, MHS, reviews recent data in lower-risk myelodysplastic syndrome and discusses the evolving treatment landscape.